MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts
The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
MicroRNAs comprise a broad class of small non-coding RNAs that control expression of complementary target messenger RNAs. Dysregulation of microRNAs by several mechanisms has been described in various disease states including cardiac disease. Whereas previous studies of cardiac disease have focused on microRNAs that are primarily expressed in cardiomyocytes, the role of microRNAs expressed in other cell types of the heart is unclear. Here we show that microRNA-21 (miR-21, also known as Mirn21) regulates the ERK-MAP kinase signalling pathway in cardiac fibroblasts, which has impacts on global cardiac structure and function. miR-21 levels are increased selectively in fibroblasts of the failing heart, augmenting ERK-MAP kinase activity through inhibition of sprouty homologue 1 (Spry1). This mechanism regulates fibroblast survival and growth factor secretion, apparently controlling the extent of interstitial fibrosis and cardiac hypertrophy. In vivo silencing of miR-21 by a specific antagomir in a mouse pressure-overload-induced disease model reduces cardiac ERK-MAP kinase activity, inhibits interstitial fibrosis and attenuates cardiac dysfunction. These findings reveal that microRNAs can contribute to myocardial disease by an effect in cardiac fibroblasts. Our results validate miR-21 as a disease target in heart failure and establish the therapeutic efficacy of microRNA therapeutic intervention in a cardiovascular disease setting.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Epigenetic manipulation through long non-coding RNAs, miRNA modulators, and other oligonucleotides has yielded promising outcomes in experimental settings.162–165”
From Senescence-induced inflammation: an important player and key therapeutic target in atherosclerosis (2020) · cites this paper as [162]
Citations
Cites
1 retracted
Rockman, H. A., Ross, R. S., Harris, A. N., Knowlton, K. U., Steinhelper, M. E., Field, L. J., Ross, J., & Chien, K. R. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.18.8277 · Cited by 797
RetractedBartel (2004) · doi:10.1016/s0092-8674(04)00045-5 · Cited by 34,714
The functions of animal microRNAs
Ambros, V. (2004) · Nature · doi:10.1038/nature02871 · Cited by 10,728
Silencing of microRNAs in vivo with ‘antagomirs’
Krützfeldt, J., Rajewsky, N., Braich, R., Rajeev, K. G., Tuschl, T., Manoharan, M., & Stoffel, M. (2005) · Nature · doi:10.1038/nature04303 · Cited by 3,949
Self-citationA microRNA component of the p53 tumour suppressor network
He, L., He, X., Lim, L. P., de Stanchina, E., Xuan, Z., Liang, Y., Xue, W., Zender, L., Magnus, J., Ridzon, D., et al. (2007) · Nature · doi:10.1038/nature05939 · Cited by 2,692
A synthetic inhibitor of the mitogen-activated protein kinase cascade.
Dudley, D. T., Pang, L., Decker, S. J., Bridges, A. J., & Saltiel, A. R. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.17.7686 · Cited by 2,679
MicroRNA-133 controls cardiac hypertrophy
Carè, A., Catalucci, D., Felicetti, F., Bonci, D., Addario, A., Gallo, P., Bang, M.-L., Segnalini, P., Gu, Y., Dalton, N. D., et al. (2007) · Nature Medicine · doi:10.1038/nm1582 · Cited by 1,776
Control of Stress-Dependent Cardiac Growth and Gene Expression by a MicroRNA
van Rooij, E., Sutherland, L. B., Qi, X., Richardson, J. A., Hill, J., & Olson, E. N. (2007) · Science · doi:10.1126/science.1139089 · Cited by 1,657
Dysregulation of Cardiogenesis, Cardiac Conduction, and Cell Cycle in Mice Lacking miRNA-1-2
Zhao, Y., Ransom, J. F., Li, A., Vedantham, V., von Drehle, M., Muth, A. N., Tsuchihashi, T., McManus, M. T., Schwartz, R. J., & Srivastava, D. (2007) · Cell · doi:10.1016/j.cell.2007.03.030 · Cited by 1,429
Yang, B., Lin, H., Xiao, J., Lu, Y., Luo, X., Li, B., Zhang, Y., Xu, C., Bai, Y., Wang, H., et al. (2007) · Nature Medicine · doi:10.1038/nm1569 · Cited by 1,138
Cited by
Items 501–600 of 1,006
MicroRNAs in Atrial Fibrillation: from Expression Signatures to Functional Implications
van den Berg, N. W. E., Kawasaki, M., Berger, W. R., Neefs, J., Meulendijks, E. R., Tijsen, A. J., & de Groot, J. R. (2017) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-017-6736-z · Cited by 101
MiR-21 protected against diabetic cardiomyopathy induced diastolic dysfunction by targeting gelsolin
Dai, B., Li, H., Fan, J., Zhao, Y., Yin, Z., Nie, X., Wang, D. W., & Chen, C. (2018) · Cardiovascular Diabetology · doi:10.1186/s12933-018-0767-z · Cited by 97
Non-canonical features of microRNAs: paradigms emerging from cardiovascular disease
Santovito, D., & Weber, C. (2022) · Nature Reviews Cardiology · doi:10.1038/s41569-022-00680-2 · Cited by 96
NF-κB mediated miR-21 regulation in cardiomyocytes apoptosis under oxidative stress
Wei, C., Li, L., Kim, I.-K., Sun, P., & Gupta, S. (2013) · Free Radical Research · doi:10.3109/10715762.2013.865839 · Cited by 98
“Although miR-21 is expressed relatively low in cardiomyocytes compared to cardiac fi broblasts [29], the expression of miR-21 is”
BackgroundFleißner, F., & Thum, T. (2010) · Antioxidants and Redox Signaling · doi:10.1089/ars.2010.3502 · Cited by 105
“MiRNAs play a crucial role in the onset and progression of cardiovascular diseases (11, 13, 113, 114).”
Self-citationMiR-449a regulates autophagy to inhibit silica-induced pulmonary fibrosis through targeting Bcl2
Han, R., Ji, X., Rong, R., Li, Y., Yao, W., Yuan, J., Wu, Q., Yang, J., Yan, W., Han, L., et al. (2016) · Journal of Molecular Medicine · doi:10.1007/s00109-016-1441-0 · Cited by 103
“[36] found that silence of miR-21 in a mouse pressure-overload-induced disease model could inhibit interstitial fibrosis by reducing cardiac EFK-MAP kinase activity.”
BackgroundFibromiRs: translating molecular discoveries into new anti-fibrotic drugs
Pottier, N., Cauffiez, C., Perrais, M., Barbry, P., & Mari, B. P. (2014) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2014.01.003 · Cited by 106
Kalsotra, A., Singh, R. K., Gurha, P., Ward, A. J., Creighton, C. J., & Cooper, T. A. (2014) · Cell Reports · doi:10.1016/j.celrep.2013.12.025 · Cited by 117
“miR-21 is known to repress the Sprouty homolog 1 (3-fold downregulated in our study), a negative regulator of ERK-MAP kinase signaling, thereby leading to fibrosis (Thum et al., 2008).”
BackgroundMicroRNAs play a role in spontaneous recovery from acute liver failure
John, K., Hadem, J., Krech, T., Wahl, K., Manns, M. P., Dooley, S., Batkai, S., Thum, T., Schulze-Osthoff, K., & Bantel, H. (2014) · Hepatology · doi:10.1002/hep.27250 · Cited by 93
“miRNAs play a role in several biological processes, including proliferation, differentiation, tissue remodeling, apoptosis, and immune responses.(2,3) Because miRNAs can be detected in clinical samples, they represent promising diagnostic markers for various diseases.”
BackgroundSelf-citationThe role of microRNAs in heart failure
Wang, H., & Cai, J. (2016) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2016.11.034 · Cited by 106
FGFR2 Abnormalities Underlie a Spectrum of Bone, Skin, and Cancer Pathologies
Katoh, M. (2009) · Journal of Investigative Dermatology · doi:10.1038/jid.2009.97 · Cited by 107
“, 2008), whereas miR-21 represses translation of functions of FGFR signaling inhibitor, Spry1 (Thum et al., 2008).”
BackgroundSimon, D., Laloo, B., Barillot, M., Barnetche, T., Blanchard, C., Rooryck, C., Marche, M., Burgelin, I., Coupry, I., Chassaing, N., et al. (2010) · Human Molecular Genetics · doi:10.1093/hmg/ddq083 · Cited by 93
“Altered microRNA-based regulation of gene expression has also been found in cardiac diseases (20,21) and cancers (reviewed in 22).”
BackgroundContribution of genetics and epigenetics to progression of kidney fibrosis
Tampe, B., & Zeisberg, M. (2013) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gft025 · Cited by 96
“MiR-21 was originally discovered to enhance fibrosis in the heart through enhancing MAPK signalling (by means of targeting the MAPK inhibitor ‘sprouty’) [28].”
Brønnum, H., Andersen, D. C., Schneider, M., Sandberg, M. B., Eskildsen, T., Nielsen, S. B., Kalluri, R., & Sheikh, S. P. (2013) · PLoS ONE · doi:10.1371/journal.pone.0056280 · Cited by 92
“Although miRNAs primarily are believed to fine-tune biological processes, the impact of these miRNAs exert quite substantial effects on the cellular level, and anti-miR-21 treatment may revert in vivo cardiac fibrosis as shown in mouse models [22].”
BackgroundResultSchroen, B., & Heymans, S. (2012) · Cardiovascular Research · doi:10.1093/cvr/cvr268 · Cited by 93
Cooley, N., Cowley, M. J., Lin, R. C. Y., Marasco, S. F., Wong, C. Y., Kaye, D. M., Dart, A. M., & Woodcock, E. A. (2011) · Physiological Genomics · doi:10.1152/physiolgenomics.00111.2011 · Cited by 97
A Review of the Molecular Mechanisms Underlying Cardiac Fibrosis and Atrial Fibrillation
Sygitowicz, G., Maciejak, A., & Sitkiewicz, D. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10194430 · Cited by 111
“Fibronectin COL—collagen; ERK—extracellular signal-regulated kinase; ERK-MAPK—extracellular signal-regulated kinase signaling pathway and mitogen-activated protein kinase signaling pathway; PI3K-AKT—Phosphatidylinositol 3- kinase—protein kinase B; Snail 1—zinc finger protein; Spry 1—protein Sprouty homolog 1; Sox 5, -…”
BackgroundInfluentialUtility of Circulating MicroRNAs as Clinical Biomarkers for Cardiovascular Diseases
Kondkar, A. A., & Abu‐Amero, K. K. (2015) · BioMed Research International · doi:10.1155/2015/821823 · Cited by 98
“miR-21 levels were found to increase in cardiac fibroblasts of the failing heart as a result of increased activation of ERK-MAP kinase signaling cascade through inhibition of Sprouty 1 (SPRY1) and pharmacological inhibition of miR-21 resulted in antihypertrophic and antifibrotic effects [69].”
BackgroundKirchhof, P., Medicine, E. C. R. A. E. A. W. S. O. P., Sipido, K. R., Medicine, E. C. R. A. E. A. W. S. O. P., Cowie, M. R., Medicine, E. C. R. A. E. A. W. S. O. P., Eschenhagen, T., Medicine, E. C. R. A. E. A. W. S. O. P., Fox, K. A. A., Medicine, E. C. R. A. E. A. W. S. O. P., et al. (2014) · European Heart Journal · doi:10.1093/eurheartj/ehu312 · Cited by 90
Recent Advances in RNA Therapeutics and RNA Delivery Systems Based on Nanoparticles
Shin, H., Park, S. D., Yim, Y., Kim, J., Choi, C., Won, C., & Min, D. (2018) · Advanced Therapeutics · doi:10.1002/adtp.201800065 · Cited by 101
Ahmadi, M., Yousefi, M., Abbaspour‐Aghdam, S., Dolati, S., Maleki, L. A., Eghbal‐Fard, S., Khabbazi, A., Rostamzadeh, D., Alipour, S., Shabani, M., et al. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.27207 · Cited by 97
“A recently conducted investigation showed that miRNAs are involved in several disorders and can be used as prognostic and diagnostic biomarkers (J. Lu et al., 2005; Slack & Weidhaas, 2008; Thum et al., 2008).”
BackgroundNon-viral nanocarriers for intracellular delivery of microRNA therapeutics
Bai, Z., Wei, J., Yu, C., Han, X., Qin, X., Zhang, C., Liao, W., Li, L., & Huang, W. (2019) · Journal of Materials Chemistry B · doi:10.1039/c8tb02946f · Cited by 97
Sala, L. L., Mrakic‐Sposta, S., Tagliabue, E., Prattichizzo, F., Micheloni, S., Sangalli, E., Specchia, C., Uccellatore, A. C., Lupini, S., Spinetti, G., et al. (2019) · Cardiovascular Diabetology · doi:10.1186/s12933-019-0824-2 · Cited by 99
Extracellular vesicular MicroRNA-27a* contributes to cardiac hypertrophy in chronic heart failure
Tian, C., Hu, G., Gao, L., Hackfort, B. T., & Zucker, I. H. (2020) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2020.04.032 · Cited by 97
“miRNA-21 was also increased in the failing hearts, but it was only abundant in cardiac fibroblasts rather than in cardiac fibroblast-derived EVs and had no effect on cardiomyocyte function [40].”
BackgroundWen, Z., Zheng, S., Zhou, C., Yuan, W., Wang, J., & Wang, T. (2011) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2011.01471.x · Cited by 94
“Selectively increased levels of miR-21 in CFBs of the failing heart augment ERK-MAPK activity through inhibition of sprouty homologue 1, contributing to the extent of interstitial fibrosis and cardiac hypertrophy, while the silencing of miR-21 by a specific antagomiR can inverse these adverse effects and attenuate car…”
BackgroundThe Bcl6 target gene microRNA-21 promotes Th2 differentiation by a T cell intrinsic pathway
Sawant, D. V., Wu, H., Kaplan, M. H., & Dent, A. L. (2013) · Molecular Immunology · doi:10.1016/j.molimm.2013.01.006 · Cited by 97
“The regulation of miR-21 by Bcl6 may also relate to the specific development of myocarditis in Bcl6−/− mice, as increased miR-21 expression has been associated with cardiac hypertrophy (Thum et al. 2008).”
BackgroundMicroRNA-21 Aggravates Cyst Growth in a Model of Polycystic Kidney Disease
Lakhia, R., Hajarnis, S. S., Williams, D., Aboudehen, K., Yheskel, M., Xing, C., Hatley, M. E., Torres, V. E., Wallace, D. P., & Patel, V. (2015) · Journal of the American Society of Nephrology · doi:10.1681/asn.2015060634 · Cited by 98
Davis, J., Salomonis, N., Ghearing, N., Lin, S. J., Kwong, J. Q., Mohan, A., Swanson, M. S., & Molkentin, J. D. (2015) · Nature Communications · doi:10.1038/ncomms10084 · Cited by 108
Characterization of an extensive rainbow trout miRNA transcriptome by next generation sequencing
Juanchich, A., Bardou, P., Rué, O., Gabillard, J., Gaspin, C., Bobe, J., & Guiguen, Y. (2016) · BMC Genomics · doi:10.1186/s12864-016-2505-9 · Cited by 100
“miR-21 is a well studied miRNA that is involved in different types of cancer [30, 31] and also in the development of heart disease [32].”
BackgroundCirculating miRNA-21 is a promising biomarker for heart failure
Zhang, J., Xing, Q., Zhou, X., Li, J., Li, Y., Zhang, L., Zhou, Q., & Tang, B. (2017) · Molecular Medicine Reports · doi:10.3892/mmr.2017.7575 · Cited by 97
Epigenetics in radiation-induced fibrosis
Weigel, C., Schmezer, P., Plass, C., & Popanda, O. (2014) · Oncogene · doi:10.1038/onc.2014.145 · Cited by 97
miRNA Profiling Discriminates Types of Rejection and Injury in Human Renal Allografts
Wilflingseder, J., Regele, H. M., Perco, P., Kainz, A., Soleiman, A., Mühlbacher, F., Mayer, B., & Oberbauer, R. W. (2013) · Transplantation · doi:10.1097/tp.0b013e318280b385 · Cited by 103
“The major sequence of miR-21 is one of the most discussed miRNAs in the literature and is upregulated in various pathophysiologic entities including tumors, fibrosis, and ischemic injury (15, 18, 19).”
BackgroundSun, M., Yu, H., Zhang, Y., Li, Z., & Gao, W. D. (2015) · Scientific Reports · doi:10.1038/srep18351 · Cited by 91
MicroRNAs in Heart Development
Espinoza‐Lewis, R. A., & Wang, D. (2012) · Current topics in developmental biology/Current Topics in Developmental Biology · doi:10.1016/b978-0-12-387786-4.00009-9 · Cited by 102
“miR-21, another miRNA which is dramatically upregulated during cardiac hypertrophy, has been shown to repress the expression of the sprouty gene 1 (Spry-1), a known inhibitor of the ERK–MAP kinase pathway, thus enhancing cell survival (Thum et al., 2008).”
BackgroundInfluentialCardiovascular Importance of the MicroRNA‐23/27/24 Family
BANG, C., FIEDLER, J., & THUM, T. (2012) · Microcirculation · doi:10.1111/j.1549-8719.2011.00153.x · Cited by 90
“Importantly, deregulation of miRNA expression may result in the development of diseases including cardiovascular disorders [14,30,35,36].”
BackgroundSelf-citationLi, F., Peng, J., Zheng, Q., Guo, X. Y., Tang, H., & Yao, S. (2015) · Analytical Chemistry · doi:10.1021/acs.analchem.5b00093 · Cited by 93
Predicting potential small molecule–miRNA associations based on bounded nuclear norm regularization
Chen, X., Zhou, C., Wang, C.-C., & Zhao, Y. F. (2021) · Briefings in Bioinformatics · doi:10.1093/bib/bbab328 · Cited by 92
Mechanisms of persistent atrial fibrillation
Jalife, J. (2014) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000000027 · Cited by 88
“through production of focal adhesion-associated proteins [48,52,53].”
Twaroski, D. M., Yan, Y., Olson, J. M. G., Bosnjak, Z. J., & Bai, X. (2014) · Anesthesiology · doi:10.1097/aln.0000000000000345 · Cited by 91
The emerging role of micro RNA s in cardiovascular disease
Mäegdefessel, L. (2014) · Journal of Internal Medicine · doi:10.1111/joim.12298 · Cited by 103
Beaumont, J., López, B., Hermida, N., Schroen, B., San José, G., Heymans, S., Valencia, F., Gómez-Doblas, J. J., De Teresa, E., Díez, J., et al. (2014) · Clinical Science · doi:10.1042/cs20130538 · Cited by 88
Qin, Y., Yu, Y., Dong, H., Bian, X., Guo, X., & Dong, S. (2012) · International Journal of Medical Sciences · doi:10.7150/ijms.4514 · Cited by 89
“Thum et al [26] reported that in vivo silencing of miR-21 by a specific antagomir in a mouse pressure-overload-induced disease model inhibits interstitial fibrosis and attenuates cardiac dysfunction.”
InfluentialThe role of microRNAs in chronic respiratory disease: recent insights
Stolzenburg, L. R., & Harris, A. (2017) · Biological Chemistry · doi:10.1515/hsz-2017-0249 · Cited by 92
“Systemic injection of miR-21 LNA-antimiRs in mice indicates that targeting to the kidneys and heart is achievable (Thum et al., 2008; Chau et al., 2012), suggesting that delivery to the lung could also be attained.”
Endothelium-mediated contributions to fibrosis
Sun, X., Nkennor, B., Mastikhina, O., Soon, K., & Nunes, S. S. (2019) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2019.10.015 · Cited by 100
Jiao, J., Herl, L. D., Farese, R. V., & Gao, F.-B. (2010) · PLoS ONE · doi:10.1371/journal.pone.0010551 · Cited by 89
“With that stated, miRNAs are attractive potential drug targets for FTD because antigomirs are relative small and have been used successfully in in vivo models of cardiovascular diseases [38].”
BackgroundZhang, Y., Zheng, S., Geng, Y., Xue, J., Wang, Z., Xie, X., Wang, J., Zhang, S., & Hou, Y. (2015) · PLoS ONE · doi:10.1371/journal.pone.0122674 · Cited by 89
Epigenetics in idiopathic pulmonary fibrosis
Tzouvelekis, A., & Kaminski, N. (2015) · Biochemistry and Cell Biology · doi:10.1139/bcb-2014-0126 · Cited by 92
“2010b), miR-21 has been suggested to exert a pro-fibrotic role in cardiac fibrosis by regulation of ERK/MAPK signaling pathway in cardiac fibroblasts (Thum et al. 2008).”
BackgroundPan, L., Huang, B., Ma, X., Wang, S.-Y., Feng, J., Lv, F., Liu, Y., Liu, Y., Li, C.-M., Liang, D., et al. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms16035420 · Cited by 94
Towards computational prediction of microRNA function and activity
Ulitsky, I., Laurent, L. C., & Shamir, R. (2010) · Nucleic Acids Research · doi:10.1093/nar/gkq570 · Cited by 95
“The well-studied mir-21 family is known to regulate MAPK signaling through SPRY1 (31).”
BackgroundCirculating miRNAs: Reflecting or Affecting Cardiovascular Disease?
van Empel, V. P. M., Windt, L. J. D., & Martins, P. A. D. C. (2012) · Current Hypertension Reports · doi:10.1007/s11906-012-0310-7 · Cited by 93
“Fibrosis [3, 4], angiogenesis [5, 6], and heart failure (HF) [2, 7, 8].”
BackgroundClinical reviews in allergy and immunology
Leung, D. Y. M., Ledford, D. K., Wechsler, M. E., Fulkerson, P. C., Bochner, B. S., Gauvreau, G. M., Gleich, G. J., Henkel, T., Kolbeck, R., Mathur, S. K., et al. (2012) · Cited by 87
HypoxamiR Regulation and Function in Ischemic Cardiovascular Diseases
Greco, S., Gaetano, C., & Martelli, F. (2014) · Antioxidants & Redox Signaling · doi:10.1089/ars.2013.5403 · Cited by 87
“Moreover, miR-21 contributes to myocardial disease by stimulating MAP kinase signaling in fibroblasts of failing hearts (134).”
BackgroundGuo, Y., Li, P., Bledsoe, G., Yang, Z.-R., Chao, L., & Chao, J. (2015) · Experimental Cell Research · doi:10.1016/j.yexcr.2015.06.021 · Cited by 86
“Increased miR-21 leads to Akt activation, which in turn up-regulates miR-21 in endothelial cells [12].”
BackgroundFrom fish to amphibians to mammals: in search of novel strategies to optimize cardiac regeneration
Ausoni, S., & Sartore, S. (2009) · The Journal of Cell Biology · doi:10.1083/jcb.200810094 · Cited by 93
“It is interesting that in a mouse model of heart failure, specifi c inhibition of the interstitial fi brogenic response has an impact on cardiac hypertrophy and dysfunction, which suggests that fi broblasts control the cardiomyocyte response to pathological stimuli ( Thum et al., 2008 ).”
BackgroundChen, L., Wang, X., Ha, T., Hu, Y., Liu, L., Zhang, X., Yu, H., Miao, J., Kao, R. L., Kalbfleisch, J. H., et al. (2015) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2015.10.011 · Cited by 87
Local Delivery of miR-21 Stabilizes Fibrous Caps in Vulnerable Atherosclerotic Lesions
Jin, H. H., Li, D. Y., Chernogubova, E., Sun, C., Busch, A., Eken, S. M., Saliba‐Gustafsson, P., Winter, H., Winski, G., Raaz, U., et al. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.01.011 · Cited by 92
Complexity of Murine Cardiomyocyte miRNA Biogenesis, Sequence Variant Expression and Function
Humphreys, D. T., Hynes, C. J., Patel, H. R., Wei, G. H., Cannon, L., Fatkin, D., Suter, C. M., Clancy, J. L., & Preiss, T. (2012) · PLoS ONE · doi:10.1371/journal.pone.0030933 · Cited by 86
“For example, overexpression of miR-210 in the mouse model improved ventricular performance and decreased apoptosis after myocardial infarction [6], while inhibition of miR-21 reduced pathological remodeling and fibrosis in response to pressure overload [7].”
miRNAs in pancreatic cancer: Therapeutic potential, delivery challenges and strategies
Chitkara, D., Mittal, A., & Mahato, R. I. (2014) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2014.09.006 · Cited by 92
Diabetic Cardiomyopathy: Current Approach and Potential Diagnostic and Therapeutic Targets
Gîlcă-Blanariu, G.-E., Ștefănescu, G., Bădulescu, O. V., Tănase, D. M., Bararu, I., & Ciocoiu, M. (2017) · Journal of Diabetes Research · doi:10.1155/2017/1310265 · Cited by 92
“Data from experimental studies emphasize the contribution of miR-21 in stimulating MAP kinase signaling inmouse fibroblasts, thus promoting fibrosis and contractility alterations as features of DCM in diabetic animal models [6, 15, 41].”
Wang, B., Wang, H., Zhang, M., Ji, R., Wei, J., Xin, Y., & Jiang, X. M. (2020) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.15479 · Cited by 100
Zhang, G., Li, N., Zhu, L., Zhu, Q., Li, F., Yang, C., Han, Q., Lv, Y., Zhou, Z.-H., & Liu, Z. (2015) · Oncotarget · doi:10.18632/oncotarget.3662 · Cited by 92
Matrix as an Interstitial Transport System
Fan, D., Creemers, E. E., & Kassiri, Z. (2014) · Circulation Research · doi:10.1161/circresaha.114.302335 · Cited by 88
“MiR-21 is elevated in pressure overload(142) and ischemic cardiomyopathy(143) and reported to trigger myocardial fibrosis because its silencing prevented fibrosis in pressure overloaded cardiomyopathy.(142) Consistently, miR-21–deficient mice were protected against renal injury and fibrosis.”
BackgroundCharrier, A., Chen, R., Chen, L., Kemper, S., Hattori, T., Takigawa, M., & Brigstock, D. R. (2014) · Journal of Cell Communication and Signaling · doi:10.1007/s12079-014-0220-3 · Cited by 91
MicroRNAs as pharmacological targets in diabetes
Mao, Y., Mohan, R., Zhang, S., & Tang, X. (2013) · Pharmacological Research · doi:10.1016/j.phrs.2013.06.005 · Cited by 91
Verma, S. K., Garikipati, V. N. S., Krishnamurthy, P., Schumacher, S. M., Grisanti, L. A., Cimini, M., Cheng, Z., Khan, M., Yue, Y., Benedict, C., et al. (2017) · Circulation · doi:10.1161/circulationaha.117.027889 · Cited by 85
MiR-21-5p regulates extracellular matrix degradation and angiogenesis in TMJOA by targeting Spry1
Ma, S., Zhang, A., Li, X., Zhang, S., Liu, S., Zhao, H., Wu, S., Chen, L., Ma, C., & Zhao, H. (2020) · Arthritis Research & Therapy · doi:10.1186/s13075-020-2145-y · Cited by 84
miRNAs and regulation of cell signaling
Ichimura, A., Ruike, Y., Terasawa, K., & Tsujimoto, G. (2011) · The FEBS Journal · doi:10.1111/j.1742-4658.2011.08087.x · Cited by 84
Maloyan, A., Muralimanoharan, S., Huffman, S., Cox, L. A., Nathanielsz, P. W., Myatt, L., & Nijland, M. J. (2013) · Physiological Genomics · doi:10.1152/physiolgenomics.00050.2013 · Cited by 86
Bone Morphogenetic Protein 9 Reduces Cardiac Fibrosis and Improves Cardiac Function in Heart Failure
Morine, K., Qiao, X., York, S., NATOV, P. S., Paruchuri, V., Zhang, Y., Aronovitz, M. J., Karas, R. H., & Kapur, N. K. (2018) · Circulation · doi:10.1161/circulationaha.117.031635 · Cited by 89
Searching for MiR-acles in Cardiac Fibrosis
van Rooij, E., & Olson, E. N. (2009) · Circulation Research · doi:10.1161/circresaha.108.192492 · Cited by 94
Mechanisms underlying the influence of oestrogen on cardiovascular physiology in women
Novella, S., Pérez‐Cremades, D., Mompeón, A., & Hermenegildo, C. (2019) · The Journal of Physiology · doi:10.1113/jp278063 · Cited by 96
“This miRNA has been implicated in myocardial hypertrophy by regulating mitogen-activated protein kinase (MAPK) signalling in fibroblasts (Thum et al. 2008).”
BackgroundKumar, D., Narang, R., Sreenivas, V., Rastogi, V., Bhatia, J., Saluja, D., & Srivastava, K. (2020) · Genes · doi:10.3390/genes11020164 · Cited by 83
“MiR-21, on the other hand, has previously been studied for its role in the pathogenesis of MI, ischemia/reperfusion injury and thus identified to have its multifunctional role in cardiovascular system [41,42].”
BackgroundOpposing roles of miR-21 and miR-29 in the progression of fibrosis in Duchenne muscular dystrophy
Zanotti, S., Gibertini, S., Curcio, M., Savadori, P., Pasanisi, M. B., Morandi, L. O., Cornelio, F., Mantegazza, R., & Mora, M. (2015) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2015.04.013 · Cited by 89
Mach, N., Plancade, S., Pacholewska, A., Lecardonnel, J., Rivière, J., Moroldo, M., Vaiman, A., Morgenthaler, C., Beinat, M., Nevot, A., et al. (2016) · Scientific Reports · doi:10.1038/srep22932 · Cited by 85
Emerging Roles for MicroRNAs in Perioperative Medicine
Neudecker, V., Brodsky, K. S., Kreth, S., Ginde, A. A., & Eltzschig, H. K. (2015) · Anesthesiology · doi:10.1097/aln.0000000000000969 · Cited by 93
MicroRNAs: new players in heart failure
Rigaud, V. O. C., Fernandes-Silva, M. M., Guimarães, G. V., Bacal, F., & Bocchi, E. A. (2012) · Molecular Biology Reports · doi:10.1007/s11033-012-2352-y · Cited by 92
Regulation of Cardiac MicroRNAs by Bone Marrow Mononuclear Cell Therapy in Myocardial Infarction
Iekushi, K., Seeger, F. H., Aßmus, B., Zeiher, A. M., & Dimmeler, S. (2012) · Circulation · doi:10.1161/circulationaha.111.079699 · Cited by 83
Myofibroblasts in the Infarct Area: Concepts and Challenges
Daskalopoulos, E. P., Janssen, B. J., & Blankesteijn, W. M. (2012) · Microscopy and Microanalysis · doi:10.1017/s143192761101227x · Cited by 90
“Hence, silencing of miRNA-21 could be of therapeutic interest ~Thum et al., 2008!.”
BackgroundCaviglia, J. M., Yan, J., Jang, M. K., Gwak, G., Affò, S., Yu, L., Olinga, P., Friedman, R. A., Chen, X., & Schwabe, R. F. (2017) · Hepatology · doi:10.1002/hep.29627 · Cited by 88
“Antimirs of different lengths have been reported to ameliorate or not affect cardiac fibrosis (14-16).”
InfluentialFibroblast GSK-3α Promotes Fibrosis via RAF-MEK-ERK Pathway in the Injured Heart
Umbarkar, P., Tousif, S., Singh, A. P., Anderson, J. C., Zhang, Q., Tallquist, M. D., Woodgett, J. R., & Lal, H. (2022) · Circulation Research · doi:10.1161/circresaha.122.321431 · Cited by 88
Restoration of Altered MicroRNA Expression in the Ischemic Heart with Resveratrol
Mukhopadhyay, P., Mukherjee, S., Ahsan, K., Bagchi, A., Pacher, P., & Das, D. K. (2010) · PLoS ONE · doi:10.1371/journal.pone.0015705 · Cited by 81
“miR-21 were shown to regulate the ERKMAP kinase signalling pathway in cardiac fibroblasts, which has role on global cardiac structure and function [24].”
BackgroundDeng, R., Tang, L., Tian, Q., Wang, Y., Lin, L., & Li, J. (2014) · Angewandte Chemie · doi:10.1002/ange.201309388 · Cited by 83
Cheng, H.-L., Fu, C., Kuo, W.-C., Chen, Y., Chen, Y.-S., Lee, Y.-M., Li, K.-H., Chen, C., Ma, H., Huang, P.-C., et al. (2018) · Lab on a Chip · doi:10.1039/c8lc00386f · Cited by 86
MicroRNAs: Emerging biomarkers for atrial fibrillation
Komal, S., Yin, J., Wang, S., Huang, C., Tao, H., Dong, J., Han, S., & Zhang, L. (2019) · Journal of Cardiology · doi:10.1016/j.jjcc.2019.05.018 · Cited by 83
González, A., Richards, M., de Boer, R. A., Thum, T., Arfsten, H., Hülsmann, M., Falcão‐Pires, I., Díez, J., Foo, R., Chan, M. Y., et al. (2022) · European Journal of Heart Failure · doi:10.1002/ejhf.2493 · Cited by 86
Self-citationA Cardiac-enriched MicroRNA, miR-378, Blocks Cardiac Hypertrophy by Targeting Ras Signaling
Nagalingam, R. S., Sundaresan, N. R., Gupta, M. P., Geenen, D. L., Solaro, R. J., & Gupta, M. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.442384 · Cited by 89
“In fibroblasts,miR-21 promotes fibroblast differentiation and its expression is induced by hypertrophy agonists (47), whereas miR-29 and miR-30c inhibit fibrosis, their expression levels decline in response to hypertrophic stimuli (48, 51–53).”
BackgroundRetractedMu, J., Pang, Q., Guo, Y., Chen, J., Zeng, W., Huang, Y., Zhang, J., & Feng, B. (2013) · PLoS ONE · doi:10.1371/journal.pone.0058622 · Cited by 81
“[43] reported that miR-21 silencing with a specific antagomir prevented cardiac dysfunction in a mouse model of heart failure.”
BackgroundMethodMicroRNAs as important regulators of the NLRP3 inflammasome
Zamani, P., Oskuee, R. K., Atkin, S. L., Navashenaq, J. G., & Sahebkar, A. (2019) · Progress in Biophysics and Molecular Biology · doi:10.1016/j.pbiomolbio.2019.05.004 · Cited by 82
Huang, Z., Chen, J., Regan, J. N., Maguire, C. T., Tang, R., Dong, X. R., Majesky, M. W., & Wang, D.-Z. (2010) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.110.213306 · Cited by 83
Adoptive Transfer of Regulatory T Cells Protects against Coxsackievirus B3-Induced Cardiac Fibrosis
Cao, Y., Xu, W., & Xiong, S. (2013) · PLoS ONE · doi:10.1371/journal.pone.0074955 · Cited by 79
“Depression of cardiac ERK-mitogen-activated protein kinases (MAPKs) activity is closely related with reduced cardiac fibroblast survival, which in turn alleviates fibrosis, remodelling and cardiac dysfunction [38].”
BackgroundKishore, R., Verma, S. K., Mackie, A. R., Vaughan, E. E., Abramova, T. V., Aiko, I., & Krishnamurthy, P. (2013) · PLoS ONE · doi:10.1371/journal.pone.0060161 · Cited by 80
“For instance, miR-29 has been shown to inhibit fibrosis by targeting collagen and fibrillin-1 [9], miR-133a negatively regulates connective tissue growth factor (CTGF) [10] and miR-21 targets sprouty homologue 1 [8] and phosphatase and tensin homologue [25]].”
BackgroundResultInfluentialMicroRNA-539 Is Up-regulated in Failing Heart, and Suppresses O-GlcNAcase Expression
Muthusamy, S., DeMartino, A. M., Watson, L. J., Brittian, K. R., Zafir, A., Dassanayaka, S., Hong, K. U., & Jones, S. P. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.578682 · Cited by 84
Portable point-of-care diagnostic devices
Zhang, W., Guo, S., Carvalho, W. S. P., Jiang, Y., & Serpe, M. J. (2016) · Analytical Methods · doi:10.1039/c6ay02158a · Cited by 84
Lavall, D., Jacobs, N., Mahfoud, F., Kolkhof, P., Böhm, M., & Laufs, U. (2019) · Biochemical Pharmacology · doi:10.1016/j.bcp.2019.07.001 · Cited by 82
Webber, M. R., Jackson, S. P., Moon, J., & Captur, G. (2020) · Cardiology and Therapy · doi:10.1007/s40119-020-00199-y · Cited by 87
McKinsey, T. A., Foo, R., Anene-Nzelu, C. G., Travers, J. G., Vagnozzi, R. J., Weber, N., & Thum, T. (2022) · Cardiovascular Research · doi:10.1093/cvr/cvac142 · Cited by 90
Self-citationWhat Causes a Broken Heart—Molecular Insights into Heart Failure
Barry, S. P., & Townsend, P. A. (2010) · International review of cytology · doi:10.1016/s1937-6448(10)84003-1 · Cited by 84
Schramm, C., Fine, D. M., Edwards, M. A., Reeb, A. N., & Krenz, M. (2012) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00665.2011 · Cited by 78
“This question is of high interest, since, recently, cardiac fibroblast-specific mechanisms have been identified that are critical in the respective pathomechanism (44).”
BackgroundLiu, S., Li, W., Xu, M., Huang, H., Wang, J., & Chen, X. (2014) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2014.07.747 · Cited by 86
Micro RNA ‐503 promotes angiotensin II‐induced cardiac fibrosis by targeting Apelin‐13
Zhou, Y., Deng, L., Zhao, D., Chen, L., Yao, Z., Guo, X., Liu, X., Lv, L., Leng, B., Xu, W., et al. (2016) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.12754 · Cited by 78
Metadata
- Authors
- Thum, T., Gross, C., Fiedler, J., Fischer, T., Kissler, S., Bussen, M., Galuppo, P., Just, S., Rottbauer, W., Frantz, S., Castoldi, M., Soutschek, J., Koteliansky, V., Rosenwald, A., Basson, M. A., Licht, J. D., Pena, J. T. R., Rouhanifard, S. H., Muckenthaler, M. U., Tuschl, T., Martin, G. R., Bauersachs, J., & Engelhardt, S.
- Affiliations
- University of Würzburg (DE)
- Deutsche Forschungsgemeinschaft (DE)
- University of California, San Francisco (US)
- Heidelberg University (DE)
- Regulus Therapeutics (United States) (US)
- Alnylam Pharmaceuticals (United States) (US)
- King's College London (GB)
- Northwestern University (US)
- Rockefeller University (US)
- Technical University of Munich (DE)
- Corresponding author
- Bauersachs, Johann
- Engelhardt, Stefan
- ORCID
- Thum, Thomas
- Gross, Carina
- Fiedler, Jan
- Fischer, Thomas
- Kissler, Stephan
- Galuppo, Paolo
- Just, Steffen
- Rottbauer, Wolfgang
- Frantz, Stefan
- Castoldi, Mirco
- Rosenwald, Andreas
- Basson, M. Albert
- Licht, Jonathan D.
- Pena, John T. R.
- Rouhanifard, Sara H.
- Muckenthaler, Martina U.
- Tuschl, Thomas
- Bauersachs, Johann
- Engelhardt, Stefan
- Venue
- Nature
- Published
- 2008-11-30
- Volume
- 456
- Issue
- 7224
- Pages
- 980-984
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2132093971
- Cited by
- 2,349
- References
- 30
- Citations by year
- 2026: 62 · 2025: 70 · 2024: 71 · 2023: 76 · 2022: 106 · 2021: 131 · 2020: 151 · 2019: 138 · 2018: 153 · 2017: 167 · 2016: 150 · 2015: 200 · 2014: 183 · 2013: 203 · 2012: 176
- FWCI
- 75.20
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Research Portal (King's College London) (submittedVersion)
- mediaTUM – the media and publications repository of the Technical University Munich (Technical University Munich) (submittedVersion)
- Funders
- National Cancer Institute (R01CA078711, R01 CA 78711, R01CA059998)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac Fibrosis and Remodeling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › MicroRNA in disease regulation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Congenital heart defects research
- Keywords
- miR-21, cardiac fibroblasts, heart failure, SPRY1, interstitial fibrosis, cardiac hypertrophy, microRNA silencing, antagomir, fibroblast survival, therapeutic target, cardiomyocytes
- MeSH terms
- Animals, Cell Line, Cell Survival, Cells, Cultured, Disease Models, Animal, Fibroblasts, Humans, Male, Mice, Transgenic, Cardiomyopathies, Gene Silencing, MAP Kinase Signaling System, Myocytes, Cardiac, MicroRNAs, Extracellular Signal-Regulated MAP Kinases, Mice, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.